Compare Inovio Pharmaceuticals Inc (INO) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs J M Smucker Co — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while J M Smucker Co trades at $113.71 (market cap $11.97B). The key difference: J M Smucker Co is far larger — about 134.1× Inovio Pharmaceuticals Inc's market cap, and J M Smucker Co pays a 3.93% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | SJM | |
|---|---|---|
Market Cap | $89.27M | $11.97B |
Sector | Health | Consumer Staples |
52-Week High | $2.87 | $117.05 |
52-Week Low | $1.05 | $89.53 |
Enterprise Value | $60.28M | $19.00B |
Dividend Yield | — | 3.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
J.M. Smucker (SJM) trades at $112.66, up 0.58% today, with a bullish technical signal and strong analyst consensus. Recent earnings beat expectations in Q4 2025 and Q1 2026, though Q2 2026 results are pending. The company maintains a solid dividend, recently increased to $1.12 per share, and benefits from growth in Uncrustables and coffee segments. However, negative net income margin and ROE highlight profitability challenges amid revenue growth to $8.73 billion in 2025.
SJM presents a mixed outlook: valuation metrics like P/E of 22.05 and P/S of 1.32 suggest reasonable pricing, but persistent net losses and high debt pose risks. Analyst price targets average $123.18, implying upside, yet investors must weigh competitive pressures and volatile cash flows against dividend stability and brand strength in the consumer staples sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
